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 Regulation of renal blood flow and 
glomerular filtration rate is highly 
depen dent on the contractile status of 
the aff erent arteriole. Arteriolar tone is 
determined by humoral and paracrine 
factors, autoregulation, and renal sym-
pathetic nerve activity. Th e study by Lai 
 et al. 1 (this issue) provides important 
new information about the interaction 
between the sympathetic  nervous system 
(norepinephrine) and angiotensin II for 
the regulation of aff erent arteriolar con-
tractility. Th e authors show an enhanced 
calcium-independent contractile 
response to angiotensin II in perfused 
aff erent arterioles treated with norepine-
phrine before the angiotensin II 
administration. 
 The renal resistance vessels include 
aff erent and eff erent glomerular arterioles. 
Changes in the diameter of pre- and post-
glomerular vessels are involved in the 
regulation of renal blood fl ow, glomerular 
fi ltration rate, and medullary blood fl ow, 
with important consequences for salt and 
water homeostasis. Furthermore, the 
renal vascular segments are aff ected in 
several pathological conditions, such as 
diabetes and hypertension. Therefore, 
regulation of aff erent arteriolar tone is 
extremely important, and the actions of 
vasoconstrictor agents in the renal vascu-
lar bed have been explored in numerous 
studies. Angiotensin II is a powerful agent 
that directly constricts vascular smooth–
muscle cells, regulates sodium homeosta-
sis, and aff ects the sympathetic nervous 
system. An increased angiotensin II con-
centration due to activation of the renin –
 angiotensin system causes an increase 
in renal vascular resistance by eliciting 
vasoconstriction initiated by activation 
of angiotensin II type 1 (AT 1 ) receptors. 2 
In addition, the renal aff erent arteriole is 
innervated by renal sympathetic nerve 
fi bers, which release norepine phrine upon 
stimulation. An increased sympathetic 
activity decreases renal blood flow by 
stimulation of   1A -adrenoceptors that 
cause aff erent arteriolar constriction; in 
addition, the renin secretion rate and 
renal tubular sodium reabsorption are 
increased. 3 Furthermore,   2 -adrenocep-
tors have also been suggested to be 
involved in norepinephrine-elicited 
aff e rent arteriolar constriction. 4 Th e re-
sultant interaction between a stimulated 
sympathetic nervous system and a stimu-
lated renin – angiotensin system has been 
pre viously investigated; however, the 
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 Lai  et al. provide important new information regarding the interaction 
between the sympathetic and renin – angiotensin systems in the 
regulation of glomerular afferent arteriolar contractility. Their study 
demonstrates a calcium-independent enhanced contractile response to 
angiotensin II following norepinephrine administration. The interplay 
between the norepinephrine- and angiotensin II – stimulated pathways 
could potentially be important in physiological as well as 
pathophysiological situations with increased sympathetic nervous 
system activity, such as hypertension. 
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mechanisms involved in the interplay at 
the level of preglomerular arterioles have 
been unclear. 
 At the level of the afferent arteriole, 
Lai and co-workers 1 (this issue) demons-
trated an enhanced afferent arteriolar 
vasoconstrictor response to angiotensin II 
following transient norepinephrine treat-
ment (that is, angiotensin II treatment 
aft er application and subsequent washout 
of norepinephrine). The contractile 
effect of angiotensin II was changed 
from an EC 50 of about 10   −  9  M (angio-
tensin II alone) to an EC 50 of about 
10   −  12  M (angio tensin II following nore-
pinephrine). Th ese data suggest that in 
the presence of an increased sympathetic 
nervous system activity, angiotensin II at 
physiologically relevant concentrations is 
cable of eliciting a powerful increase in 
aff erent arteriolar resistance. Circulating 
plasma angio tensin II concentrations are 
around 50 – 100  p M , and concentrations 
up to 3 – 5  n M are found in the renal inter-
stitial fl uid. 5 Interestingly, the potentiated 
vasoconstrictor eff ect is independent of 
changes in intracellular calcium concen-
trations and occurs through an   -adreno-
ceptor-activated calcium sensitization of 
the aff erent arteriolar contractile appara-
tus through phosphorylation of myosin 
phosphatase, target subunit 1 (MYPT1 ) 
( Figure 1 ). 
 It is well known that the angiotensin II-
induced renovasoconstrictor response can 
be infl uenced by other substances. In the 
aff erent arterioles, adenosine restores the 
angiotensin II-induced contraction aft er 
tachyphylaxis via calcium sensitization of 
the vascular smooth–muscle contractile 
apparatus. 6 In addition, the angiotensin II 
constrictor response is significantly 
reduced in the adenosine A1 receptor 
knockout mouse. 7 Th e cross-talk between 
angio tensin II AT 1 receptors and adeno-
sine A1 receptors has been explored in 
numerous studies. However, the potential 
interaction between norepinephrine and 
angiotensin II-mediated contraction at 
the level of the renal vasculature has been 
previously unclear. 
 The contractile activity of smooth-
muscle cells is regulated primarily 
by changes in intracellular calcium 
see original article on page 953
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by other vasoconstrictor agents also be 
enhanced by norepinephrine? Further-
more, 2  min of exposure time was used in 
the study by Lai  et al. , 1 but is there a neces-
sary exposure time for norepinephrine? 
Th e concentration of norepinephrine used 
in the study by Lai  et al. 1 (10   m ) seems 
high compared with phy siological plasma 
concentrations, where plasma concentra-
tions up to 5 – 10  n m are found only in 
pathophysiological conditions such as in 
patients with congestive heart failure. 
However, the local concentration of nore-
pinephrine at the site of adrenergic vari-
cosities on the aff erent arteriole is probably 
the concentration that is important for the 
mechanism described, although it would 
be of interest to know the threshold con-
centration for the enhancing eff ect of nore-
pinephrine. Th e answers to these questions 
would shed more light on the physiologi-
cal importance of this new mechanism. 
 Th e fi ndings in the paper by Lai  et al. 1 
could potentially be important in both 
physiological and pathophysio logical situ-
ations with an increased sympathetic nerve 
activity and increased norepinephrine 
release. Elevated sympathetic nerve activ-
ity has been associated with the develop-
ment of essential hypertension, congestive 
heart failure, and nephrotic syndrome, 3 
and it has been suggested that renal 
nerves contribute to the enhanced aff er-
ent arteriolar response to angiotensin II 
during hypertension. 10 The interplay 
between activation of the sympathetic 
nervous system with   -adrenoceptor 
activation and angio tensin II-induced 
renal vasoconstriction provides a mecha-
nism by which physio logically relevant 
concentrations of angiotensin II may be 
important for regulation of the renal vas-
cular resis tance in pathophysiological 
states such as hypertension. 
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 concentration as the Ca 2  +   / calmodulin 
complex activates myosin light chain 
kinase (MLCK) and contraction is initi-
ated by phosphorylation of the regulatory 
light chain of myosin. Th e phosphoryla-
tion status of myosin light chain is deter-
mined by the  ba lance  between 
phosphorylation by myosin light chain 
kinase and dephosphorylation by myosin 
light chain phosphatase (MLCP). The 
phosphorylation level for a given calcium 
concentration determines the calcium 
sensitivity of the contractile apparatus. 
Myosin phosphatase is composed of three 
subunits, of which myosin phosphatase, 
target subunit 1 (MYPT1), is involved in 
regulation of the myosin phosphatase 
activity. Inhibition of myosin phos-
phatase can be achieved by phosphoryla-
tion of MYPT1 via Rho kinase or protein 
kinase C. 8 Th e enhanced aff erent arteri-
olar constrictor response to angiotensin 
II aft er norepinephrine treatment that Lai 
 et al. 1 found is due to increased calcium 
sensitivity of the contractile apparatus 
through phosphorylation of MYPT1, but 
other signaling components that partici-
pate in this mechanism are unclear. It has 
recently been suggested that phospho-
lipase C and Rho kinase are important co-
participants in the interaction between 
  2 -adrenoceptor activation and the simul-
taneous activation of the angiotensin II 
AT 1 receptor. 9 Th e new concept of a nore-
pinephrine-mediated calcium-independ-
ent enhancement of the contractile 
response to subsequent angio tensin II 
administration reminds us of the com-
plexity of the regulatory pathways deter-
mining the aff erent arteriolar tone. It is 
important to take into account the inter-
play between vasoactive agents when renal 
hemodynamic responses are investigated 
and to consider the fact that previous 
stimulation of the vasculature can have 
signifi cant eff ects on subsequent stimuli. 
 Th e unique fi nding by Lai  et al. 1 also 
raises several questions and perspectives 
for further experimental studies. Is the 
enhancing constrictor eff ect of norepine-
phrine specifi c for angiotensin II? Could 
the aff erent arteriolar constrictor response 
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 Figure 1  |  Interaction between   -adrenoceptors and angiotensin II receptors. Stimulation 
of   -adrenoceptors   by norepinephrine (NE) leads to increased calcium sensitivity in the afferent 
arteriole through phosphorylation of myosin phosphatase target subunit 1 (MYPT1). This 
inhibits myosin light chain phosphatase (MLCP) activity and increases the level of phosphorylated 
myosin light chain (MLC), increasing the contractility and calcium sensitivity of the afferent 
arteriole in response to angiotensin II (Ang II). This could potentially occur through a 
phospholipase C (PLC)-dependent and Rho kinase – dependent pathway. CaM, calmodulin; 
IP 3 , inositol triphosphate; MLCK, myosin light chain kinase; PP1c, type 1 protein phosphatase; 
VSMC, vascular smooth - muscle cell. 
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 In trying  to study the relationships 
between vitamin D and chronic kidney 
disease (CKD), the nephrologist might 
feel like Achilles in the footrace with the 
tortoise of Zeno ’ s famous paradox ( ‘ In a 
race, the quickest runner can never over-
take the slowest, since the pursuer must 
fi rst reach the point whence the pursued 
started, so that the slower must always 
hold a lead ’ 1 ). In fact, at the time of the 
writing of this article , a quick search for 
the two key words  ‘ vitamin D ’ and  ‘ CKD ’ 
in PubMed ( www.pubmed.gov ) yielded 
2529 articles; studying four articles a day 
(that is, one hour of peaceful study a day, 
every day: a dream, for most of us!), it 
would take 632 working days to be 
updated in the matter — more than two 
years — and, in the meantime, tens or hun-
dreds of new articles would have been 
published. 
It has become evident that the amount 
of available scientifi c information is great-
er than our ability to process it, and we too, 
as scientists, envisage a prophetic sense in 
the words of an old song of Th e Police 
(1981):  ‘ Too much information running 
through my brain; too much information, 
driving me insane. ’ Th us, articles such as 
that of Mehrotra  et al. , 2 published in this 
issue, are a welcomed contribution to the 
fi eld, because such vast and comprehen-
sive studies distill solid information that 
can be useful both in daily practice and 
as a starting point for further research. In 
fact, the article by Mehrotra  et al. 2 can be 
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 Chronic kidney disease and 
vitamin D: how much is adequate ? 
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 Mehrotra  et al. demonstrate that there still is hypovitaminosis D in 
adults with chronic kidney disease (CKD) in the United States, and this 
defect is associated with increased risk for death. Definition of the 
adequate amount of vitamin D, however, is still uncertain; 
polymorphisms of the gene encoding the vitamin D receptor might be 
responsible for this uncertainty. People carrying less efficient variants of 
the receptor might need higher amounts of vitamin D. 
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considered as a meta-analysis of data gath-
ered from a large cohort (more than 3000 
subjects) of adults with CKD enrolled in 
the Th ird National Health and Nutrition 
Examination Survey (NHANES III) — a 
random sampling of community-dwelling 
individuals in the United States conduct-
ed between 1988 and 1994. Th e results are 
impressive and confi rm beyond any pos-
sible doubt something that many in the 
fi eld had suspected for a long time: there 
still is hypovitaminosis D in adults with 
CKD in the United States, and this defect 
is associated with increased risk for death. 
As with every other association study, a 
cause – eff ect relationship cannot be traced, 
but the message is clear, and it directly 
points to the question recently addressed 
in this journal,  ‘ How much vitamin D 
should we prescribe? ’ 3 
 Indeed, the defi nition itself of hypovi-
taminosis D is a tricky business: the fact 
that rickets is no longer a major public-
health problem in Western countries, as 
it was in the 1930s, does not mean that 
we are consuming enough vitamin D. 
Apparently the problems with vitamin D 
began a long time ago: as  civilization 
and the industrial revolution enabled 
 humans to work indoors and to wear 
more clothes when in the sun, these 
cultural changes reduced natural pro-
duction of vitamin D and caused defi -
ciency diseases. Because of this, in many 
countries, foods such as milk, yogurt, 
margarine, oil spreads, breakfast cereal, 
pastries, and bread are  ‘ fortifi ed ’ with 
vitamin D 2 and / or vitamin D 3 , to mini-
mize the risk of vitamin D defi ciency. 4 
In the United States and Canada, for ex-
ample, fortifi ed milk typically provides 
100 IU per glass, or one-quarter of the 
estimated adequate intake for adults over 
the age of 50. Today, adequate intake is 
defi ned as 200 IU per day from infancy 
to age 50, 400 IU per day for ages 51 – 70, 
and 600 IU per day for ages over 70. Th e 
100 % daily value used for product labels 
is 400 IU. Th e practical reality, however, 
is that, on average, the diet in the United 
States provides only 100 IU per day. But 
to which condition does the adjective 
 ‘ adequate ’ refer? (Figure 1) .
 Just to remember how fl uid the sce-
nario is, it is worth noting that, today, no 
one is sure what  ‘ adequate ’ truly means. 
